Details for Patent: 9,901,640

Which drugs does patent 9,901,640 protect, and when does it expire?

Patent 9,901,640 protects RYTARY and is included in one NDA.

This patent has twenty-five patent family members in twelve countries.

Summary for Patent: 9,901,640

Title:	Controlled release formulations of levodopa and uses thereof
Abstract:	A modified release levodopa dosage form.
Inventor(s):	Hsu; Ann (Los Altos Hills, CA), Kou; Jim (San Jose, CA), Alani; Laman (Fort Worth, TX)
Assignee:	Impax Laboratories, Inc. (Hayward, CA)
Application Number:	15/382,851
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,901,640

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-001	Jan 7, 2015		RX	Yes	No			Y			TREATMENT OF PARKINSON'S DISEASE
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-002	Jan 7, 2015		RX	Yes	No			Y			TREATMENT OF PARKINSON'S DISEASE
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No			Y			TREATMENT OF PARKINSON'S DISEASE
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes			Y			TREATMENT OF PARKINSON'S DISEASE

International Family Members for US Patent 9,901,640

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008343787
Canada	2711014
China	101910113
European Patent Office	2234963